Abstract 589P
Background
Circulating tumor DNA (ctDNA) based molecular residual disease (MRD) detection has been shown to predict prognosis and guide individualized management of colorectal cancer (CRC). The landmark point is usually set at 4-12 weeks post resection in consideration of the disturbance to cell-free DNA (cfDNA) by surgery. This study aimed to evaluate the feasibility of moving the landmark point to 1-week post resection.
Methods
The study prospectively and consecutively enrolled stage I-IV CRC patients who received R0 resection. Blood samples at baseline, post-operative day (POD) 7, POD30 and subsequent every 3-6 months surveillance were collected. The MRD status of all the samples were evaluated by the Burning Rock Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (brPROPHETTM) approach. The cfDNA level, mean tumor mutant (MTM), positive predictive value (PPV) and negative predictive value (NPV) were compared between POD7 and POD30.
Results
In total, 164 eligible patients were enrolled. The median follow-up duration was 311 days (95% CI, 296-351) up to date. The brPROPHET displayed a high sensitivity of 95.1% (155/163) for detecting ctDNA preoperatively, with 88.5%, 96.1%, 96.2%, 100% in stage I to IV, respectively. Post-resection ctDNA positive rates were decreased to 15.2% (25/164) at POD7 and 12.8% (21/164) at POD30. The cfDNA levels of POD7 were significantly higher than those of baseline and POD30 (P<0.001). However, the MTMs were similar between POD7 and POD30 (P = 0.55). The accordance between POD7 and POD30 was 91.5% (150/164). For 6-month recurrence, the PPV was 13.6% vs 15.8% for POD7 and POD30, respectively, with NPV of 100% vs 98.2%. Of the 25 ctDNA positive patients at POD7, 9 turned negative at POD30 and had significantly lower ctDNA levels at POD7 than those who didn’t (P<0.001). Patients with decreased ctDNA from POD7 to POD30 had a higher ctDNA clearance rate during surveillance than those without decreased ctDNA (100% vs 30%, P = 0.02).
Conclusions
The performance of ctDNA detection in POD7 and POD30 was similar. Shift of the landmark time to 1-week post resection may provide an easier way to evaluate MRD status for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10